Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.

Cancer
Robert J MotzerNizar M Tannir

Abstract

CheckMate 025 has shown superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma (aRCC) along with improved safety and tolerability. This analysis assesses the long-term clinical benefits of nivolumab versus everolimus. The randomized, open-label, phase 3 CheckMate 025 trial (NCT01668784) included patients with clear cell aRCC previously treated with 1 or 2 antiangiogenic regimens. Patients were randomized to nivolumab (3 mg/kg every 2 weeks) or everolimus (10 mg once a day) until progression or unacceptable toxicity. The primary endpoint was overall survival (OS). The secondary endpoints were the confirmed objective response rate (ORR), progression-free survival (PFS), safety, and health-related quality of life (HRQOL). Eight hundred twenty-one patients were randomized to nivolumab (n = 410) or everolimus (n = 411); 803 patients were treated (406 with nivolumab and 397 with everolimus). With a minimum follow-up of 64 months (median, 72 months), nivolumab maintained an OS benefit in comparison with everolimus (median, 25.8 months [95% CI, 22.2-29.8 months] vs 19.7 months [95% CI, 17.6-22.1 months]; hazard ratio [HR], 0.73; 95% CI, 0.62-0.85) with 5-year OS probabilities of 26% and 18%, resp...Continue Reading

References

Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G FyfeA C Louie
Sep 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Yoshiko IwaiNagahiro Minato
Jul 25, 2007·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·David CellaWilliam P Bro
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerSuzanne L Topalian
Dec 3, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerHans J Hammers
Mar 25, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David F McDermottMichael B Atkins
Sep 26, 2015·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 025 Investigators
Nov 1, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Toni K ChoueiriMario Sznol
Mar 1, 2018·The Oncologist·Nizar M TannirMichael B Atkins

❮ Previous
Next ❯

Citations

Jan 12, 2021·Journal for Immunotherapy of Cancer·Marion AlloucheryUNKNOWN French Network of Regional Pharmacovigilance Centers
Mar 25, 2021·Journal of Translational Medicine·Andrea BotticelliPaolo Marchetti
Mar 24, 2021·Acta Clinica Belgica·Michael SaerensWillem Lybaert
Apr 2, 2021·OncoTargets and Therapy·Yan ZhengFengmin Shao
Jun 9, 2021·Proceedings of the National Academy of Sciences of the United States of America·Yuping ZhangArul M Chinnaiyan
Jul 23, 2021·Expert Review of Anticancer Therapy·Lothar BergmannMarit Ahrens
Aug 19, 2021·The New England Journal of Medicine·Toni K ChoueiriUNKNOWN KEYNOTE-564 Investigators
Sep 3, 2021·Journal of Cancer Research and Clinical Oncology·Rui MaoDong Zhou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adenocarcinoma, Clear Cell

Clear Cell Adenocarcinoma is a tumor that arises in the female genital tract and is characterized by cells that appear clear under the microscope. Discover the latest research here.